68003-38-3
68003-38-3 结构式
基本信息
2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸
SLC25A1 inhibitor CTPI-2
2-(4'-Chloro-3'-nitrobenzenesulfonamido)benzoic acid
2-[(4-chloro-3-nitrophenyl)sulphonyl]anthranilic acid
Benzoic acid, 2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-
2-(4-Chloro-3-nitrophenylsulfonylamino)benzenecarboxylic acid
macrophage,carrier,CTPI-2,NSCLC,transporter,glucose,steatohepatitis,CTPI 2,Mitochondrial Metabolism,steatosis,inflammatory,inhibit,citrate,Inhibitor,mitochondrial,CTPI2
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | S2968 | 2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 CTPI-2 | 68003-38-3 | 5mg | 1384.11元 |
| 2024/04/30 | S2968 | CTPI-2 | 68003-38-3 | 10mM (1mL in DMSO) | 1613.43元 |
| 2024/04/30 | S2968 | CTPI-2 | 68003-38-3 | 100mg | 10377.1元 |
常见问题列表
| Target | Value |
|
glycolysis
() | |
|
SLC25A1
(Cell-free assay) | 3.5 μM(Kd) |
CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 (26 mg/kg; i.p.) inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC).
CTPI-2 (50 mg/kg; i.p.; alternate days for 12 weeks) completely averts weight gain in the prevention study and leads to significant weight loss in the reversion study.
CTPI-2 prevents steatohepatitis and normalizes glucose tolerance. CTPI-2 lowers the levels of circulating IL-6 while increasing anti-inflammatory IL-4 and IL-10 and also reduced the monocyte chemoattractant protein-1 and monokine-induced by interferon-γ that attract neutrophils and monocytes. CTPI-2 regulates the citrate pool, the lipogenic and the gluconeogenic pathways.
| Animal Model: | C57BL/6J mice (HFD-fed mice) |
| Dosage: | 50 mg/kg |
| Administration: | Alternate days via the intraperitoneal route for 12 weeks |
| Result: | Completely averted weight gain in the prevention study and led to significant weight loss in the reversion study. |